You are here

Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis.

Related Articles Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2017 Jan;45(2):376-378 Authors: Hartery K, O’Reilly S, Houlihan D, Doherty G, Mulcahy H, Cullen G, Sheridan J PMID: 27933688 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/27933688?dopt=Abstract

Read More

Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.

Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Inflamm Bowel Dis. 2016 Dec 07; Authors: Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K Abstract BACKGROUND: Vedolizumab is a gut-selective α4β7 integrin antagonist for the treatment of moderately to severely active Crohn’s disease (CD). Aims of this study were to characterize the efficacy and safety of vedolizumab induction and maintenance therapy in patients who were naïve to tumor…

Read More

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel DiseasesWith Need for Additional Doses Within 6 months.

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel DiseasesWith Need for Additional Doses Within 6 months. Clin Gastroenterol Hepatol. 2016 Nov 24;: Authors: Williet N, Boschetti G, Fovet M, Di Bernado T, Claudez P, Del Tedesco E, Jarlot C, Rinaldi L, Berger A, Phelip JM, Flourie B, Nancey S, Paul S, Roblin X Abstract BACKGROUND & AIMS: We investigated whether serum trough levels of vedolizumab, a humanized monoclonal antibody against integrin alpha 4 beta 7, during the induction phase of treatment can determine whether patients…

Read More

Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.

Related Articles Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Aliment Pharmacol Ther. 2016 Nov 17;: Authors: Feagan BG, Patel H, Colombel JF, Rubin DT, James A, Mody R, Lasch K Abstract BACKGROUND: Health-related quality of life (HRQL) is often diminished in patients with ulcerative colitis. AIM: To evaluate the effects of vedolizumab on HRQL in patients with ulcerative colitis. METHODS: Using maintenance phase data from the GEMINI 1 study, an analysis of covariance model was used to…

Read More

Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC.

Related Articles Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut. 2016 Oct 7;: Authors: Arijs I, De Hertogh G, Lemmens B, Van Lommel L, de Bruyn M, Vanhove W, Cleynen I, Machiels K, Ferrante M, Schuit F, Van Assche G, Rutgeerts P, Vermeire S Abstract OBJECTIVE: Lymphocyte recruitment to the inflamed gut is increased in UC. Inhibition of this cell trafficking by vedolizumab (VDZ) was successful in inducing and maintaining remission and in induction of endoscopic mucosal healing. There are no…

Read More

Response to “Preoperative Vedolizumab and Postoperative Outcomes in Inflammatory Bowel Disease: does smoke always mean fire?”

Related Articles Response to “Preoperative Vedolizumab and Postoperative Outcomes in Inflammatory Bowel Disease: does smoke always mean fire?” J Crohns Colitis. 2016 Nov 5;: Authors: Lightner AL, Loftus EV PMID: 27816935 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/27816935?dopt=Abstract

Read More

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Related Articles Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699-710 Authors: Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A, GEMINI 1 Study Group Abstract BACKGROUND: Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis. METHODS: We conducted two integrated randomized, double-blind, placebo-controlled trials of vedolizumab in patients with active disease. In the…

Read More

Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease.

Related Articles Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013 Jul;19(8):1691-9 Authors: Parikh A, Fox I, Leach T, Xu J, Scholz C, Patella M, Feagan BG Abstract BACKGROUND: Vedolizumab, a gut-selective, anti-inflammatory monoclonal antibody, has shown preliminary efficacy in ulcerative colitis (UC) and Crohn’s disease (CD). We report long-term experience with vedolizumab for active UC and CD. METHODS: After a placebo-controlled study, 38 patients with UC were randomized to a loading regimen of vedolizumab 2, 6, or 10 mg/kg on days 1, 15,…

Read More
<< Go Back